^
    4d
    Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=106, Recruiting, MonTa Biosciences ApS | N=69 --> 106 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • MBS8
    5d
    A Bioluminescence Reporter Mouse Strain for In Vivo Imaging of IFNγ Cell Localization and Function. (PubMed, Immunology)
    The validation confirmed that this model is capable of directly detecting Poly(I:C) -induced transient IFNγ, enhancing intratumoral IFNγ signals upon anti-PD-1/CTLA-4 therapy, and dynamically tracking IFNγ expression during imiquimod-induced psoriasis. This transgenic mouse model provides a powerful tool for non-invasive, longitudinal tracking of IFNγ-expressing cells, offering novel insights into IFNγ-mediated immune regulation in inflammation and cancer. It holds promise for identifying IFNγ-related therapeutic targets and predicting responses to immunotherapies.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Zyclara (imiquimod)
    8d
    Management of Extramammary Paget Disease of the Male Genital Region: A Narrative Review and Two Case Reports. (PubMed, J Clin Med)
    Non-surgical modalities-including photodynamic therapy, topical imiquimod, radiotherapy and, in advanced disease, systemic chemotherapy, HER2 targeted agents and immune checkpoint inhibitors-provide additional options in selected patients. A multidisciplinary, biomarker driven approach is essential to individualize management and improve long-term outcomes in this challenging disease.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Zyclara (imiquimod)
    11d
    IL Believe: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=320, Active, not recruiting, Ascendis Pharma Oncology Division A/S | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
    16d
    A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer (clinicaltrials.gov)
    P1/2, N=75, Recruiting, SURGE Therapeutics | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    resiquimod (STM-416)
    19d
    Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance. (PubMed, Immun Inflamm Dis)
    Our findings indicate that Grg3 confers protective effects in a murine model of imiquimod-induced psoriasis-like dermatitis. The potential therapeutic properties of Grg3 potentially involve modulation of NLRP3 inflammasome activation, suppression of NF-κB signaling, and restoration of Th17/Treg cell homeostasis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • RELA (RELA Proto-Oncogene)
    |
    Zyclara (imiquimod)
    22d
    CAN1012 in OED, DCIS, and LCIS. (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Providence Health & Services
    New P1 trial
    25d
    Synergistic Activation of NO and Cytokine Production by TLR3 With TLR5 or TLR7 Agonists in RAW 264.7 Cells. (PubMed, Microbiol Immunol)
    This study investigated the individual and combinatorial effects of TLR3 Poly(I:C), TLR5 (Flagellin), and TLR7 (Imiquimod) ligands on nitric oxide (NO) production and pro-inflammatory cytokine expression in RAW 264.7 mouse macrophage cells...These findings highlight a potent crosstalk between TRIF-dependent (TLR3) and MyD88-dependent (TLR7, TLR5) signaling pathways, leading to amplified immune activation. Our study highlights the potential of synergistic TLR ligand combinations as powerful immunomodulators, offering promising avenues for the rational design of more effective vaccine adjuvants and innovative strategies in cancer immunotherapy.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR3 (Toll Like Receptor 3) • TLR5 (Toll Like Receptor 5) • TLR7 (Toll Like Receptor 7)
    |
    Zyclara (imiquimod)
    26d
    Single-cell transcriptomics reveals keratinocyte dynamic processes associated with S100a4 expression in psoriasiform dermatitis. (PubMed, Front Immunol)
    Using CRISPR/Cas9 to generate S100a4 gene knockout mice, imiquimod was continuously applied to the back skin to induce the psoriasis disease model...Our findings suggest a potential pathogenic role for S100A4 in psoriasis and highlight previously uncharacterized cell-specific transcriptional landscapes and regulatory mechanisms. Our results provide novel insights into the complex pathology of psoriasis and could offer important clues for the development of new targeted therapeutic strategies.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • S100A4 (S100 calcium binding protein A4)
    |
    Zyclara (imiquimod)
    1m
    Efficacy and Safety of Microneedling Combined with Topical Medications for Psoriatic Nails (ChiCTR2600116372)
    P4, N=60, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital
    New P4 trial
    |
    Zyclara (imiquimod)
    1m
    Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer (ChiCTR2500112788)
    P2, N=45, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    carboplatin • albumin-bound paclitaxel • Zyclara (imiquimod)
    1m
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)